Answers are grounded in this paper and cite their sources.
Sodium-glucose transporter-2 inhibitors (SGLT2i) are commonly used for the treatment of Type 2 Diabetes Mellitus, offering additional benefits in non-diabetic patients with conditions such as chronic kidney disease and heart failure. However, SGLT2i have been associated with an increased risk of euglycemic diabetic ketoacidosis (DKA). This case series describes three cases of patients who developed euglycemic DKA while taking SGLT2i.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: